Glaukos (NYSE:GKOS) COO Joseph Gilliam Sells 4,502 Shares

Glaukos Corporation (NYSE:GKOS) COO Joseph Gilliam sold 4,502 shares of the company’s stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $124.65, for a total value of $561,174.30. Following the completion of the sale, the chief operating officer directly owned 92,366 shares in the company, valued at approximately $11,513,421.90. The trade was a 4.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Glaukos Price Performance

GKOS opened at $119.96 on Friday. The company has a current ratio of 5.20, a quick ratio of 4.47 and a debt-to-equity ratio of 0.09. The company has a market cap of $6.89 billion, a price-to-earnings ratio of -77.89 and a beta of 0.67. The stock has a fifty day simple moving average of $110.53 and a two-hundred day simple moving average of $96.27. Glaukos Corporation has a 12-month low of $73.16 and a 12-month high of $161.78.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.11. The firm had revenue of $133.54 million for the quarter, compared to the consensus estimate of $122.55 million. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. The company’s revenue was up 38.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.28) EPS. Research analysts predict that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Glaukos

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC increased its holdings in shares of Glaukos by 2.6% in the 1st quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock worth $766,000 after purchasing an additional 198 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in shares of Glaukos by 1,405.9% during the first quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock valued at $252,000 after purchasing an additional 2,390 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Glaukos by 41.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock valued at $22,636,000 after buying an additional 67,668 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Glaukos during the second quarter valued at $1,245,000. Finally, GAMMA Investing LLC increased its holdings in Glaukos by 56.0% in the 2nd quarter. GAMMA Investing LLC now owns 2,109 shares of the medical instruments supplier’s stock worth $218,000 after buying an additional 757 shares in the last quarter. 99.04% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

GKOS has been the subject of several recent research reports. The Goldman Sachs Group reiterated a “buy” rating and set a $138.00 target price on shares of Glaukos in a report on Friday, January 9th. BTIG Research reaffirmed a “buy” rating and set a $116.00 price objective on shares of Glaukos in a research report on Friday, January 2nd. Needham & Company LLC reiterated a “buy” rating and set a $125.00 price objective on shares of Glaukos in a research note on Wednesday, January 14th. Citigroup boosted their target price on Glaukos from $113.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Finally, Stephens increased their target price on Glaukos from $115.00 to $145.00 and gave the stock an “overweight” rating in a research note on Friday, January 2nd. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Glaukos currently has an average rating of “Moderate Buy” and an average target price of $131.38.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.